相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer
Guru Sonpavde et al.
FUTURE ONCOLOGY (2020)
A conserved dendritic-cell regulatory program limits antitumour immunity
Barbara Maier et al.
NATURE (2020)
RETROSPECTIVE POOLED ANALYSIS OF EPACADOSTAT CLINICAL STUDIES IDENTIFIES DOSES REQUIRED FOR MAXIMAL PHARMACODYNAMIC EFFECT IN ANTI-PD-1 COMBINATION STUDIES
Michael Smith et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
Alexander J. Muller et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy
Theodore S. Johnson et al.
CANCER RESEARCH (2018)
Indoximod modulates AhR-driven transcription of genes that control immune function
Erik L. Brincks et al.
CANCER RESEARCH (2018)
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.
Nathan Bahary et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC).
Gautam Gopalji Jha et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Phase I study of indoximod in patients with advanced malignancies
Hatem H. Soliman et al.
ONCOTARGET (2016)
Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma
Y. Zakharia et al.
EUROPEAN JOURNAL OF CANCER (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Rikke B. Holmgaard et al.
CELL REPORTS (2015)
A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component.
Howard Colman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity
Tracy L. McGaha et al.
IMMUNOLOGICAL REVIEWS (2012)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
Evan M. Hersh et al.
INVESTIGATIONAL NEW DRUGS (2011)
Reprogrammed Foxp3+ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8+ T Cell Priming in Naive Mice
Madhav D. Sharma et al.
IMMUNITY (2010)
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes
Madhav D. Sharma et al.
BLOOD (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
Madhav D. Sharma et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
De-Yan Hou et al.
CANCER RESEARCH (2007)
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
DH Munn et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
G Frumento et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
分享论文
